At least 30 minutes should elapse after an alendronate dose before taking aluminum-containing drugs.Īlendronate Cholecalciferol: (Moderate) Concomitant administration of oral alendronate with aluminum-containing medications (e.g., sucralfate) may interfere with the absorption of alendronate. Taking these drugs simultaneously may result in reduced bioavailability of dolutegravir.Īlendronate: (Moderate) Concomitant administration of oral alendronate with aluminum-containing medications (e.g., sucralfate) may interfere with the absorption of alendronate. The chemical structure of sucralfate contains aluminum, which can bind dolutegravir in the GI tract. Because stability data are not available, the author recommended no longer than a 2-week expiration date.Ībacavir Dolutegravir Lamivudine: (Moderate) Administer dolutegravir 2 hours before or 6 hours after taking sucralfate. Label with 'refrigerate', 'shake well', and 'protect from light'. Package in disposable enema bottles or rectal syringes in 2 g/20 mL packages. Then, add more methylcellulose to make a final volume of 1200 mL. This will form a paste until the rest of the methylcellulose is added and it is important to allow this phase to occur to establish 'high-shear' forces that will allow the powder to be well distributed when the enema suspension is finished. Add the powder to 300 mL of 10% methylcellulose solution, mixing well. One article reports a case of rectal administration of the commercially available 10% sucralfate oral suspension to deliver a 2 g/20 mL dosage rectally twice daily however, the effect of formulation excipients on the rectal mucosal or with regard to safety, efficacy, or tolerability are not known.Īnother article reported an extemporaneous formula for 10% sucralfate rectal enema as follows: Crush one-hundred-twenty (120) sucralfate 1-g tablets to a fine powder using a large mortar and pestle. Stability data and expiration date recommendations are generally not available for these extemporaneous enemas. ![]() Water, or 5% or 10% methylcellulose solutions, have been used as diluents for the oral tablets for compounding the dosages reported. While doses have been characterized in literature reports, extemporaneous formulations for those doses have not been standardized. Marketed formulations are not available in the U.S.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |